Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer

Pratishtha Singh, Deblina Raychaudhuri, Bidisha Chakraborty, Sukadev Meher, Aminah J. Tannir, A.k. Majumdar, Jessalyn Hawkins, Yun Xiong, Philip Lorenzi, Padmanee Sharma, Patrick G. Pilié, Sangeeta GoswamibioRxiv 2024 · DOI

TL;DR

Mutations in the KDM6A gene act as a "double-edged sword" in bladder cancer: they significantly improve a patient's response to immunotherapy (ICT) but simultaneously drive resistance to standard cisplatin-based chemotherapy. This happens because the loss of KDM6A triggers a two-pronged shift—breaking the cell's DNA repair machinery and "starving" the tumor’s immunosuppressive environment of lactate.

Abstract

Mutations in epigenetic regulators are frequent in bladder cancer, yet their impact on therapeutic efficacy remains poorly defined. This study investigates KDM6A, a histone demethylase frequently mutated in this disease. Retrospective clinical analyses reveal that KDM6A mutations correlate with improved overall survival (OS) in patients receiving immune checkpoint therapy (ICT), but are associated with lower OS in those undergoing cisplatin-based chemotherapy. Mechanistically, KDM6A loss downregulates DNA repair pathways, increasing genomic instability and ICT sensitivity while inducing cisplatin resistance. Additionally, KDM6A deficiency reduces glycolysis and lactate production, impairing histone lactylation in Regulatory T cells (Tregs) and diminishing their immunosuppressive function. These findings highlight KDM6A mutation status as a potential biomarker for personalizing bladder cancer treatment.

Introduction

Bladder cancer is a leading cause of cancer-related mortality. While traditional cisplatin-based chemotherapy and newer immune checkpoint therapies (ICT) are available, clinicians lack robust biomarkers to predict which patients will benefit most from each approach. KDM6A, an epigenetic regulator, is mutated in approximately 26% of bladder cancer cases. This study explores the role of KDM6A in modulating therapeutic responses, providing a mechanistic basis for patient stratification.

Methods

The researchers employed a multi-faceted approach combining clinical data and preclinical models:

  • Clinical Correlation: Retrospective analysis of major patient cohorts, including IMVigor210, TCGA, MSK_2018, and HCRN, to link KDM6A mutations with survival outcomes.
  • Preclinical Modeling: CRISPR-Cas9 was used to delete Kdm6a in murine bladder cancer cell lines (MB49) to observe therapeutic responses in vivo.
  • Mechanistic Profiling: RNA-seq, ChIP-seq, and mass spectrometry (LC-MS/MS) were used to analyze gene expression, epigenetic marks (specifically histone lactylation), and metabolic shifts.
  • Immune Analysis: Mass cytometry (CyTOF) characterized the tumor microenvironment (TME) and immune cell populations, focusing on the ratio of cytotoxic T cells to Tregs.

Key Insights

Genomic Instability and Therapy Response

Loss of KDM6A leads to the downregulation of DNA mismatch repair (MMR) and double-strand break repair (DSBR) genes. This results in increased genomic instability, making the tumor more immunogenic and responsive to ICT. However, because cisplatin efficacy depends on a functional MMR system to trigger apoptosis in response to DNA damage, KDM6A-deficient cells exhibit reduced sensitivity to chemotherapy.

Metabolic and Epigenetic Regulation of Tregs

KDM6A deficiency suppresses glycolytic activity, leading to reduced intratumoral lactate levels. This metabolic shift prevents histone lactylation (H3K9la and H3K18la) in Tregs, which is necessary for the expression of key immunosuppressive genes like Foxp3, Tgfb, and Pdcd1. Consequently, the loss of KDM6A reduces the expansion of PD-1<sup>hi</sup> Tregs, improving the ratio of cytotoxic T cells to Tregs and enhancing the anti-tumor response.

Results

Clinical data demonstrated a clear divergence in survival based on KDM6A status: mutant patients fared significantly better on ICT but worse on chemotherapy. Preclinical models confirmed that Kdm6a loss improves response to anti-PD-1 therapy while lowering sensitivity to cisplatin.

KDM6A plays a differential role in modulating the response to ICT and cisplatin-based chemotherapy.

Conclusion

This study identifies KDM6A as a critical determinant of therapeutic response in bladder cancer. By acting as a biomarker for both ICT sensitivity and chemotherapy resistance, KDM6A mutation status can guide the development of personalized treatment algorithms. Future research may investigate the potential of PARP inhibitors to target the DNA repair vulnerabilities identified in KDM6A-deficient tumors.

Summary updated

Abstract

Abstract Mutations in genes encoding critical epigenetic regulators are frequently noted in bladder cancer, however, the impact of these mutations on therapeutic efficacy is unclear. One of the most common driver mutations in bladder cancer occurs in the KDM6A gene, which encodes a histone demethylase that promotes gene transcription. Retrospective analyses of patients with bladder cancer demonstrated that KDM6A mutations correlate with improved overall survival (OS) with immune checkpoint therapy (ICT), while they are associated with lower OS in patients undergoing cisplatin-based chemotherapy. Mechanistic studies utilizing CRISPR-Cas9 mediated deletion of Kdm6a showed reduced expression of DNA mismatch repair (MMR) and DNA double-stranded base repair (DSBR) genes in tumor cells with improved response to anti-PD-1 therapy and attenuated sensitivity to cisplatin-based chemotherapy in preclinical models of bladder cancer. Additionally, the loss of Kdm6a -mediated reduction in glycolysis and intratumoral lactate accumulation impaired histone 3 lysine 9 lactylation (H3K9la) and histone 3 lysine 18 lactylation (H3K18la) in Tregs with concurrent decrease in the expression of key genes including Foxp3, Tgfb and Pdcd1 and their immune-suppressive function. Further, reduced expansion of PD-1 hi Tregs improved the ratio of cytotoxic T cells to Tregs and response to anti-PD-1 therapy in Kdm6a deficient tumor-bearing mice. Collectively, this study provided key insights into the role of KDM6A-mediated epigenetic regulation of DNA repair and metabolic reprogramming which potentially govern response to chemotherapy and ICT thus highlighting the utility of KDM6A mutation status for patient stratification and development of personalized treatment algorithms.
BibTeX
@misc{singh2024loss,
  author = {Pratishtha Singh and Deblina Raychaudhuri and Bidisha Chakraborty and Sukadev Meher and Aminah J. Tannir and A.K. Majumdar and Jessalyn Hawkins and Yun Xiong and Philip Lorenzi and Padmanee Sharma and Patrick G. Pilié and Sangeeta Goswami},
  title = {{Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer}},
  year = {2024},
  doi = {10.1101/2024.10.31.621396},
  howpublished = {bioRxiv},
}
Figure